Transferrin Receptor 2 Ectodomain for BMP-Driven Ossification Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sclerosing diseases, such as Fibrodysplasia ossificans progressiva (FOP), are limited in their effectiveness and often come with significant side effects, failing to halt the progression of uncontrolled bone formation outside the skeleton.
Innovation Solution
A protein with an amino acid sequence having at least 70% identity to SEQ ID NO. 1, specifically targeting the transforming growth factor-β (TGF-β)/bone morphogenetic proteins (BMP) family, is used to inhibit the BMP signaling pathway and reduce bone formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If conventional treatments (steroids, NSAIDs, resections) are used for sclerosing diseases, then symptoms are alleviated, but the progression of uncontrolled bone formation cannot be halted and side effects occur
Solution Approach 1:
The patent introduces a specific protein or antibody that acts as an intermediary to bind to and neutralize excess BMP signaling molecules. This mediator selectively interferes with the pathological BMP-ACVR1 interaction without broadly suppressing all bone formation, thereby halting disease progression while avoiding the side effects of non-specific therapies like steroids.
Solution Approach 2:
The invention changes the therapeutic parameter from non-specific anti-inflammatory or anti-osteogenic agents to a targeted molecular agent that specifically modulates BMP signaling activity. This parameter change enables selective inhibition of pathological bone formation while preserving normal bone physiology.
2Productivity
If steroids are used to inhibit bone formation, then bone formation is reduced, but significant side effects occur (obesity, diabetes, brittle skin, muscle wasting)
Solution Approach 1:
The patent applies local quality by designing a therapy that acts specifically on the pathological site of uncontrolled bone formation through targeted BMP inhibition. The treatment affects only areas with abnormal BMP signaling activity, leaving healthy tissues and normal bone formation processes unaffected, thus avoiding systemic side effects.
Solution Approach 2:
A targeted protein or antibody serves as an intermediary that selectively binds to excess BMP molecules in affected tissues, preventing them from activating ACVR1 receptors. This localized intermediary action provides bone formation inhibition without the systemic hormonal effects that cause side effects like obesity, diabetes, and muscle wasting.
3Quantity of substance
If resection is performed to remove ossified tissue, then existing bone formation is removed, but recurrence probability remains high (up to 80%)
Solution Approach 1:
The patent applies preliminary action by administering BMP-inhibiting therapy before or during the resection procedure. This pre-treatment prevents further bone formation and may reduce the extent of ossification, making surgery more effective and reducing the likelihood of recurrence by addressing the underlying pathological signaling.
Solution Approach 2:
The invention ensures continuity of useful action by maintaining BMP inhibition both during and after resection. This continuous therapeutic action prevents recurrence by continuously blocking the pathological BMP signaling that would otherwise drive new bone formation in the resected area, reducing recurrence probability from 80% to significantly lower levels.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The protein effectively inhibits bone formation in sclerosing diseases, reducing the progression of ossification and minimizing side effects compared to conventional therapies.
Implementation Method 1
The protein according to the invention binds members of the transforming growth factor -β (TGF-β)/bone morphogenetic proteins (bone morphogenetic proteins, BMP) family, preferably BMPs, especially preferably BMP-2, BMP-4, BMP-6 and BMP-7
Data Source
Figure 1
Figure 2A~2B
Figure 3A~3B
AI summary
The invention relates to a protein for use in the diagnosis and treatment of primary or secondary sclerosing diseases, a fusion protein, a nucleotide sequence and a vector and a pharmaceutical composition for use in the diagnosis and treatment of primary or secondary sclerosing diseases.